Anders Bøgevig (CEO)
Anders is responsible for building new business areas and Chemnotia’s product portfolio. He combines a strong background in synthetic chemistry with experience in project leadership and new business opportunities from roles he has held in the past. Anders got his PhD in 2001 at Århus University, Denmark, under supervision of Prof. Karl-Anker Jørgensen. After postdoctoral work with Hans Adolfsson at Stockholm University, he joined AstraZeneca R&D, Södertälje, in 2003 as a synthesis specialist at the Process R&D unit. During the time at AstraZeneca he took part in, and lead, specialist groups working together with project teams with scale-up, route design, and development of synthesis planning software.
Bo Olsson (Chairman)
Bo´s extensive strategic Leadership Experience from Process Research & Development activities is in many ways complementary to that of the founders. He is accountable for defining the Core Value Proposition of Chemnotia:s offerings and the quality of Strategic Planning. He also brings a valuable overview of the Chemical and Pharmaceutical industry and an important Network of Contacts. Bo is a Master of Science in Chemical Engineering from the Royal Institute of Technology, and has had a number of Leadership Positions in the Chemical and Pharmaceutical Industry. He was VP for AstraZeneca Process R&D during 1997-2011. After assisting the R&D Leadership in reducing the R&D footprint in Södertälje he joined the Association of Swedish Industry member IKEM in 2012. IKEM has around 1400 member companies in the Chemical- and Pharmaceutical Industry and Bo is there accountable for Research and Innovation. Bo´s Leadership Carreer is surrounded by a number of radical Examples of effectiveness improvements and successful projects over the years.
Tobias Rein (CSO)
Tobias has long experience of R&D in different areas of organic and medicinal chemistry, and his main focus is to ensure that Chemnotia applies science and innovation of the highest possible level to solve our customers’ challenges. Tobias obtained his PhD in 1989 from the Royal Institute of Technology (KTH), Stockholm, Sweden, working with Prof. Björn Åkermark. After postdoctoral work with Prof. Stephen F. Martin at the University of Texas, Austin, he has held positions as Assistant Professor at KTH, Associate Professor at the Technical University of Denmark (DTU), Lyngby, and as Adjunct Professor at KTH. Tobias joined AstraZeneca R&D, Södertälje, in 2000 and was first leading project chemistry teams at the Department of Medicinal Chemistry. In 2006, he moved to the Process R&D unit to build and lead a team of specialists having overall responsibility for synthesis planning, route scouting, and solving synthetic challenges for the drug development projects. In addition, he worked with building synthetic chemistry capability globally across AstraZeneca.
Olle Westblom (Product Manager)